May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy
Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56% incidence of acute kidney injury in PRISM-MDR's active treatment arm, higher than the expected rate of 25-40%. The company will provide an update in July.

Opdivo misses in GBM
Bristol-Myers Squibb Co. (NYSE:BMY) said PD-1 inhibitor Opdivo nivolumab plus radiation missed the primary endpoint of improving overall survival vs. temozolomide plus radiation in the Phase III CheckMate -498 trial to treat newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme. The Phase III CheckMate -548 trial is evaluating Opdivo plus temozolomide and radiation in the indication, with an estimated primary completion date in February 2022, according to ClinicalTrials.gov...